Nrf2 is controlled by two distinct β-TrCP recognition motifs in its Neh6 domain, one of which can be modulated by GSK-3 activity

Oncogene

Volumn 32, Issue 32, 2013, Pages 3765-3781

  Chowdhry, S ^a   Zhang, Y ^a   McMahon, M ^a   Sutherland, C ^b   Cuadrado, A ^c   Hayes, J D ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

^c HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

Author keywords

b TrCP; drug resistance; GSK 3; Nrf2; oxidative stress; ubiquitylation

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; ACROLEIN; BETA TRANSDUCIN REPEAT CONTAINING PROTEIN; CHLORAMBUCIL; CISPLATIN; GLUTAMATE CYSTEINE LIGASE; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE ALPHA 1; GLUTATHIONE TRANSFERASE M1; GLYCOGEN SYNTHASE KINASE 3; HEME OXYGENASE 1; KELCH LIKE ECH ASSOCIATED PROTEIN 1; MEMBRANE PROTEIN; MESSENGER RNA; NEH6 PROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG;

ARTICLE; ASSAY; BINDING SITE; BIOTINYLATION; CATALYSIS; CONTROLLED STUDY; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MODULATION; MOLECULAR RECOGNITION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; UBIQUITINATION;

ANIMALS; ANTINEOPLASTIC AGENTS; BETA-TRANSDUCIN REPEAT-CONTAINING PROTEINS; BINDING SITES; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GLYCOGEN SYNTHASE KINASE 3; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; NF-E2-RELATED FACTOR 2; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTEIN STRUCTURE, TERTIARY; UBIQUITINATION;

EID: 84881476323     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.388     Document Type: Article

References (63)

1. Kensler TW, Wakabayashi N, Biswal S. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol 2007; 47: 89-116.
2. Nioi P, McMahon M, Itoh K, Yamamoto M, Hayes JD. Identification of a novel Nrf2-regulated antioxidant response element (ARE) in the mouse NAD(P)H:quinone oxidoreductase 1 gene: reassessment of the ARE consensus sequence. Biochem J 2003; 374: 337-348.
3. Hayes JD, McMahon M, Chowdhry S, Dinkova-Kostova AT. Cancer chemoprevention mechanisms mediated through the Keap1-Nrf2 pathway. Antioxid Redox Signal 2010; 13: 1713-1748.
4. McMahon M, Itoh K, Yamamoto M, Hayes JD. Keap1-dependent proteasomal degradation of transcription factor Nrf2 contributes to the negative regulation of antioxidant response element-driven gene expression. J Biol Chem 2003; 278: 21592-21600.
5. Nguyen T, Sherratt PJ, Huang HC, Yang CS, Pickett CB. Increased protein stability as a mechanism that enhances Nrf2-mediated transcriptional activation of the antioxidant response element. Degradation of Nrf2 by the 26 S proteasome. J Biol Chem 2003; 278: 4536-4541.
6. Stewart D, Killeen E, Naquin R, Alam S, Alam J. Degradation of transcription factor Nrf2 via the ubiquitin-proteasome pathway and stabilization by cadmium. J Biol Chem 2003; 278: 2396-2402.
7. McMahon M, Thomas N, Itoh K, Yamamoto M, Hayes JD. Dimerization of substrate adaptors can facilitate cullin-mediated ubiquitylation of proteins by a 'tethering' mechanism: a two-site interaction model for the Nrf2-Keap1 complex. J Biol Chem 2006; 281: 24756-24768.
8. Tong KI, Padmanabhan B, Kobayashi A, Shang C, Hirotsu Y, Yokoyama S et al. Different electrostatic potentials define ETGE and DLG motifs as hinge and latch in oxidative stress response. Mol Cell Biol 2007; 27: 7511-7521.
9. Petroski MD, Deshaies RJ. Function and regulation of cullin-RING ubiquitin ligases. Nat Rev Mol Cell Biol 2005; 6: 9-20.
10. Kobayashi A, Kang MI, Okawa H, Ohtsuji M, Zenke Y, Chiba T et al. Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol Cell Biol 2004; 24: 7130-7139.
11. Zhang DD, Lo SC, Cross JV, Templeton DJ, Hannink M. Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex. Mol Cell Biol 2004; 24: 10941-10953.
12. Kobayashi M, Li L, Iwamoto N, Nakajima-Takagi Y, Kaneko H, Nakayama Y et al. The antioxidant defence system Keap1-Nrf2 comprises a multiple sensing mechanism for responding to a wide range of chemical compounds. Mol Cell Biol 2009; 29: 493-502.
13. McMahon M, Lamont DJ, Beattie KA, Hayes JD. Keap1 perceives stress via three sensors for the endogenous signaling molecules nitric oxide, zinc, and alkenals. Proc Natl Acad Sci USA 2010; 107: 18838-18843.
14. Singh A, Misra V, Thimmulappa RK, Lee H, Ames S, Hoque MO et al. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med 2006; 3: e420.
15. Singh A, Boldin-Adamsky S, Thimmulappa RK, Rath SK, Ashush H, Coulter J et al. RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy. Cancer Res 2008; 68: 7975-7984.
16. Ohta T, Iijima K, Miyamoto M, Nakahara I, Tanaka H, Ohtsuji M et al. Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth. Cancer Res 2008; 68: 1303-1309.
17. Wang R, An J, Ji F, Jiao H, Sun H, Zhou D. Hypermethylation of the Keap1 gene in human lung cancer cell lines and lung cancer tissues. Biochem Biophys Res Commun 2008; 373: 151-154.
18. Konstantinopoulos PA, Spentzos D, Fountzilas E, Francoeur N, Sanisetty S, Grammatikos AP et al. Keap1 mutations and Nrf2 pathway activation in epithelial ovarian cancer. Cancer Res 2011; 71: 5081-5089.
19. Muscarella LA, Parrella P, D'Alessandro V, la Torre A, Barbano R, Fontana A et al. Frequent epigenetics inactivation of KEAP1 gene in non-small cell lung cancer. Epigenetics 2011; 6: 710-719.
20. Yoo NJ, Kim HR, Kim YR, An CH, Lee SH. Somatic mutations of the KEAP1 gene in common solid cancers. Histopathology 2012; 60: 943-952.
21. Shibata T, Ohta T, Tong KI, Kokubu A, Odogawa R, Tsuta K et al. Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy. Proc Natl Acad Sci USA 2008; 105: 13568-13573.
22. Jiang T, Chen N, Zhao F, Wang XJ, Kong B, Zheng W et al. High levels of Nrf2 determine chemoresistance in type II endometrial cancer. Cancer Res 2010; 70: 5486-5496.
23. DeNicola GM, Karreth FA, Humpton TJ, Gopinathan A, Wei C, Frese K et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 2011; 475: 106-109.
24. McMahon M, Thomas N, Itoh K, Yamamoto M, Hayes JD. Redox-regulated turnover of Nrf2 is determined by at least two separate protein domains, the redoxsensitive Neh2 degron and the redox-insensitive Neh6 degron. J Biol Chem 2004; 279: 31556-31567.
25. Salazar M, Rojo AI, Velasco D, de Sagarra RM, Cuadrado A. Glycogen synthase kinase-3b inhibits the xenobiotic and antioxidant cell response by direct phosphorylation and nuclear exclusion of the transcription factor Nrf2. J Biol Chem 2006; 281: 14841-14851.
26. Rojo AI, Sagarra MR, Cuadrado A. GSK-3b down-regulates the transcription factor Nrf2 after oxidant damage: relevance to exposure of neuronal cells to oxidative stress. J Neurochem 2008; 105: 192-202.
27. Rojo AI, Rada P, Egea J, Rosa AO, Ló pez MG, Cuadrado A. Functional interference between glycogen synthase kinase-3b and the transcription factor Nrf2 in protection against kainate-induced hippocampal cell death. Mol Cell Neurosci 2008; 39: 125-132.
28. Rada P, Rojo AI, Chowdhry S, McMahon M, Hayes JD, Cuadrado A. SCF/b-TrCP promotes glycogen synthase kinase 3-dependent degradation of the Nrf2 transcription factor in a Keap1-independent manner. Mol Cell Biol 2011; 31: 1121-1133.
29. Wu G, Xu G, Schulman BA, Jeffrey PD, Harper JW, Pavletich NP. Structure of a b-TrCP1-Skp1-b-catenin complex: destruction motif binding and lysine specificity of the SCF(b-TrCP1) ubiquitin ligase. Mol Cell 2003; 11: 1445-1456.
30. Tsuchiya Y, Morita T, Kim M, Iemura S, Natsume T, Yamamoto M et al. Dual regulation of the transcriptional activity of Nrf1 by b-TrCP-and Hrd1-dependent degradation mechanisms. Mol Cell Biol 2011; 31: 4500-4512.
31. Sutherland C, Leighton I, Cohen P. Inactivation of glycogen synthase kinase-3b by phosphorylation; new kinase connections in insulin and growth factor signalling. Biochem J 1993; 296: 15-19.
32. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995; 378: 785-789.
33. Frescas D, Pagano M. Deregulated proteolysis by the F-box proteins SKP2 and b-TrCP: tipping the scales of cancer. Nat Rev Cancer 2008; 8: 438-449.
34. Aberle H, Bauer A, Stappert J, Kispert A, Kemler R. b-catenin is a target for the ubiquitin-proteasome pathway. EMBO J 1997; 16: 3797-3804.
35. Winston JT, Strack P, Beer-Romero P, Chu CY, Elledge SJ, Harper JW. The SCFb-TRCPubiquitin ligase complex associates specifically with phosphorylated destruction motifs in IkBa and b-catenin and stimulates IkBa ubiquitination in vitro. Genes Dev 1999; 13: 270-283.
36. Meyer L, Deau B, Forejtn?́ková H, Dumé nil D, Margottin-Goguet F, Lacombe C et al. b-Trcp mediates ubiquitination and degradation of the erythropoietin receptor and controls cell proliferation. Blood 2007; 109: 5215-5222.
37. Zhao B, Li L, Tumaneng K, Wang CY, Guan KL. A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCFb-TRCP. Genes Dev 2010; 24: 72-85.
38. Fong A, Sun SC. Genetic evidence for the essential role of b-transducin repeatcontaining protein in the inducible processing of NF-kB2/p100. J Biol Chem 2002; 277: 22111-22114.
39. Watanabe N, Arai H, Nishihara Y, Taniguchi M, Watanabe N, Hunter T et al. M-phase kinases induce phospho-dependent ubiquitination of somatic Wee1 by SCFb-TrCP. Proc Natl Acad Sci USA 2004; 101: 4419-4424.
40. Kaidanovich-Beilin O, Woodgett JR. GSK-3: functional insights from cell biology and animal models. Front Mol Neurosci 2011; 4: 40.
41. Yu R, Lei W, Mandlekar S, Weber MJ, Der CJ, Wu J et al. Role of a mitogenactivated protein kinase pathway in the induction of phase II detoxifying enzymes by chemicals. J Biol Chem 1999; 274: 27545-27552.
42. Alam J, Wicks C, Stewart D, Gong P, Touchard C, Otterbein S et al. Mechanism of heme oxygenase-1 gene activation by cadmium in MCF-7 mammary epithelial cells. Role of p38 kinase and Nrf2 transcription factor. J Biol Chem 2000; 275: 27694-27702.
43. Zipper LM, Mulcahy RT. Inhibition of ERK and p38 MAP kinases inhibits binding of Nrf2 and induction of GCS genes. Biochem Biophys Res Commun 2000; 278: 484-492.
44. Lee JM, Hanson JM, Chu WA, Johnson JA. Phosphatidylinositol 3-kinase, not extracellular signal-regulated kinase, regulates activation of the antioxidantresponsive element in IMR-32 human neuroblastoma cells. J Biol Chem 2001; 276: 20011-20016.
45. Huang HC, Nguyen T, Pickett CB. Phosphorylation of Nrf2 at Ser-40 by protein kinase C regulates antioxidant response element-mediated transcription. J Biol Chem 2002; 277: 42769-42774.
46. Rushworth SA, Chen XL, Mackman N, Ogborne RM, O'Connell MA. Lipopolysaccharide-induced heme oxygenase-1 expression in human monocytic cells is mediated via Nrf2 and protein kinase C. J Immunol 2005; 175: 4408-4415.
47. Hwang YP, Kim HG, Han EH, Jeong HG. Metallothionein-III protects against 6-hydroxydopamine-induced oxidative stress by increasing expression of heme oxygenase-1 in a PI3K and ERK/Nrf2-dependent manner. Toxicol Appl Pharmacol 2008; 231: 318-327.
48. Sun Z, Huang Z, Zhang DD. Phosphorylation of Nrf2 at multiple sites by MAP kinases has a limited contribution in modulating the Nrf2-dependent antioxidant response. PLoS One 2009; 4: e6588.
49. Rojo AI, Medina-Campos ON, Rada P, Zúñ iga-Toalá A, Ló pez-Gazcón A, Espada S et al. Signaling pathways activated by the phytochemical nordihydroguaiaretic acid contribute to a Keap1-independent regulation of Nrf2 stability: role of glycogen synthase kinase-3. Free Radic Biol Med 2012; 52: 473-487.
50. Cohen P, Frame S. The renaissance of GSK3. Nat Rev Mol Cell Biol 2001; 2: 769-776.
51. Watai Y, Kobayashi A, Nagase H, Mizukami M, McEvoy J, Singer JD et al. Subcellular localization and cytoplasmic complex status of endogenous Keap1. Genes Cells 2007; 12: 1163-1178.
52. Seo E, Kim H, Kim R, Yun S, Kim M, Han JK et al. Multiple isoforms of b-TrCP display differential activities in the regulation of Wnt signaling. Cell Signal 2009; 21: 43-51.
53. Putters J, Slotman JA, Gerlach JP, Strous GJ. Specificity, location and function of bTrCP isoforms and their splice variants. Cell Signal 2011; 23: 641-647.
54. Lassot I, Ségé ral E, Berlioz-Torrent C, Durand H, Groussin L, Hai T et al. ATF4 degradation relies on a phosphorylation-dependent interaction with the SCFb-TrCP ubiquitin ligase. Mol Cell Biol 2001; 21: 2192-2202.
55. Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov 2009; 8: 579-591.
56. Finlay D, Patel S, Dickson LM, Shpiro N, Marquez R, Rhodes CJ et al. Glycogen synthase kinase-3 regulates IGFBP-1 gene transcription through the thymine-rich insulin response element. BMC Mol Biol 2004; 5: 15.
57. Zhang Y, Crouch DH, Yamamoto M, Hayes JD. Negative regulation of the Nrf1 transcription factor by its N-terminal domain is independent of Keap1: Nrf1, but not Nrf2, is targeted to the endoplasmic reticulum. Biochem J 2006; 399: 373-385.
58. Murai H, Okazaki M, Kikuchi A. Tyrosine dephosphorylation of glycogen synthase kinase-3 is involved in its extracellular signal-dependent inactivation. FEBS Lett 1996; 392: 153-160.
59. Ikeda S, Kishida S, Yamamoto H, Murai H, Koyama S, Kikuchi A. Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3b and b-catenin and promotes GSK-3b-dependent phosphorylation of b-catenin. EMBO J 1998; 17: 1371-1384.
60. Treier M, Staszewski LM, Bohmann D. Ubiquitin-dependent c-Jun degradation in vivo is mediated by the delta domain. Cell 1994; 78: 787-798.
61. Higgins LG, Kelleher MO, Eggleston IM, Itoh K, Yamamoto M, Hayes JD. Transcription factor Nrf2 mediates an adaptive response to sulforaphane that protects fibroblasts in vitro against the cytotoxic effects of electrophiles, peroxides and redox-cycling agents. Toxicol Appl Pharmacol 2009; 237: 267-280.
62. Midgley CA, Desterro JM, Saville MK, Howard S, Sparks A, Hay RT et al. An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo. Oncogene 2000; 19: 2312-2323.
63. MacLeod AK, McMahon M, Plummer SM, Higgins LG, Penning TM, Igarashi K et al. Characterization of the cancer chemopreventive NRF2-dependent gene battery in human keratinocytes: demonstration that the KEAP1-NRF2 pathway, and not the BACH1-NRF2 pathway, controls cytoprotection against electrophiles as well as redox-cycling compounds. Carcinogenesis 2009; 30: 1571-1580.